Thank you, Kim, and welcome everyone to our Q3 earnings call. This quarter included a number of notable developments, including earnings exceeding expectations, record free cash flow, solid fertility growth at Cooper Surgical, and the favorable completion of a significant tax matter. At Cooper Vision, however, we proactively reduced U.S. channel inventory that weighed on our results and will continue to impact Q4. Importantly, our underlying demand in the US remained healthy throughout the quarter, with consumption increasing at a mid-single digit rate, and we're now positioned to enter fiscal 2027 with a healthier channel and stronger foundation. We're also taking additional steps to strengthen Cooper Vision revenue performance, and I'll speak to these in a moment, but first I want to address the completion of the strategic review, which we announced in a separate press release today. Following a comprehensive evaluation of alternatives, the board has concluded the strategic review. As part of the process, we conducted a thorough assessment of Cooper Surgical, including a potential sale of the business, where we received significant interest and engaged with numerous parties. Ultimately, however, the board unanimously determined that shareholders are better served by continued ownership than by pursuing a transaction at this time. The board and our advisors believe several temporary factors influence valuations laid in the process, including developments related to a competitive entrant in the non hormonal IUD market and the impact of our fertility litigation settlement. These factors contributed to what we believe was a temporary disconnect between Coopersurgical's intrinsic value and the offers received, resulting in proposals that did not adequately reflect the full value and long-term potential of the business. While the formal strategic review has concluded, our commitment to enhancing shareholder value has not changed. We gain valuable insights through the process and will intensify our focus on profitable organic growth and disciplined capital allocation, including share repurchases. The board and management will also continue to evaluate opportunities to maximize long-term shareholder value and remain open to strategic alternatives that appropriately recognize the value of our operations. Turning to the quarter, CooperVision reported revenue of $717 million, essentially flat year over year. AMEA and Asia PAC performed largely in line with our expectations, while the results in the Americas reflected Cooper Vision's U.S. channel inventory reductions. Moving forward, we see opportunities to strengthen our growth globally through improved execution of our con our contract wins and product launches. And to support this effort, we're investing in expanded sales coverage, increased customer marketing programs, and enhanced commercial execution capabilities, including AI-driven targeting and analytics tools. These initiatives are already gaining traction in Asia PAC, where our new commercial leadership team is fully in place, and in the U.S., where we're actively expanding our Salesforce organization. These efforts are driving stronger customer engagement, including within our private label business, where new account wins and SKU introductions are expanding our customer footprint and deepening penetration within existing accounts. We're also continuing to invest in our distribution infrastructure, including a new packaging facility in Puerto Rico that will expand direct to consumer and direct to customer fulfillment capabilities, enhancing service levels, and supporting long-term growth. All these actions are well underway and position us to drive greater revenue growth in fiscal 2027 and beyond. Turning to products, our flagship My Day franchise continues to perform well, highlighted by double-digit growth in EMEA and double-digit consumption growth in the Americas. This performance was driven by strong customer partnerships, ongoing expansion in high value categories such as Torics and Multifocals, growing adoption of our premium MyDay Energist offering, and the successful launch of MyDay MySite. Myday Toric delivered another quarter of double-digit growth supported by the industry's broadest daily parameter range and the same market-leading toric design as BioAffinity. Myday Toric maintains a meaningful competitive advantage, offering approximately 30% more prescription options than any other daily Toric ones. Myday Multifocal also delivered another quarter of double digit growth, supported by its advanced optical design and easy-to-fit platform. With favorable demographic trends and significant room for category expansion, we continue to view multifocals as one of the most attractive growth opportunities and contact lenses. And to build on this, we are preparing to launch MyDay Toric Multifocal, extending our leadership in optics, parameter range, and clinical performance. Finally, MyDay Energist delivered another quarter of double digit growth, reflecting increasing recognition among eye care professionals and wearers of its differentiated combination of premium optics and advanced material technology. For clarity, performance varied by region, with growth in EMEA offset by softer performance in our other two regions. However, our next generation Clarity Multifocal continues to gain momentum, supported by the same proven fitting design as BioAffinity and MyDay. And we also recently completed ? the Clarity Family launch in Japan, and initial customer response has been encouraging. Turning to Bioaffinity, strength in AMIA and within our market-leading made-to-order portfolio, including Tortifocals and Extended Ranges, was offset by the inventory moves in the U.S., resulting in a flat quarter. Regarding myopia management, my site delivered another strong quarter with 20% organic growth. AMEA and the Americas led performance while softness in China weighed on Asia Pac. Although this was partially offset by growing momentum in Japan following our MySite launch earlier this year. In EMIA, growth was supported by the ongoing launch of MyDay MySite with back to school campaigns highlighting the benefits of a silicone hydrogel offering. Canada also launched Myday MySite in August, and customer feedback has been excellent. Importantly, in these markets that have Myday MySite, the Myday platform now supports patients across every stage of life, from myopia management in children through spherical, torque, multifocal, and premium lifestyle offerings in adulthood. Looking ahead, we expect my site growth to be in the low teens in Q4 against a difficult prior year comparison, resulting in roughly 20% growth for this full year and setting the stage for a promising 2027 supported by continued momentum in existing markets and the upcoming launch of My Day MySite Toric. Lastly, on Vision, we're accelerating programs tied to new product development, and that ties nicely in with the opening of our global vision center in the UK later this month.
Passages & reports (24) 2:23 Thank you, Kim, and welcome everyone to our Q3 earnings call. This quarter included a numb… Report 2:43 reduced U.S. channel inventory that weighed on our results and will continue to impact Q4.… Report 3:03 healthier channel and stronger foundation. We're also taking additional steps to strengthe… Report 3:22 concluded the strategic review. As part of the process, we conducted a thorough assessment… Report 3:42 ownership than by pursuing a transaction at this time. The board and our advisors believe … Report 4:02 contributed to what we believe was a temporary disconnect between Coopersurgical's intrins… Report 4:22 changed. We gain valuable insights through the process and will intensify our focus on pro… Report 4:41 alternatives that appropriately recognize the value of our operations. Turning to the quar… Report 5:01 inventory reductions. Moving forward, we see opportunities to strengthen our growth global… Report 5:21 execution capabilities, including AI-driven targeting and analytics tools. These initiativ… Report 5:41 including within our private label business, where new account wins and SKU introductions … Report 6:01 customer fulfillment capabilities, enhancing service levels, and supporting long-term grow… Report 6:21 in EMEA and double-digit consumption growth in the Americas. This performance was driven b… Report 6:41 delivered another quarter of double-digit growth supported by the industry's broadest dail… Report 7:00 Multifocal also delivered another quarter of double digit growth, supported by its advance… Report 7:20 on this, we are preparing to launch MyDay Toric Multifocal, extending our leadership in op… Report 7:40 advanced material technology. For clarity, performance varied by region, with growth in EM… Report 8:00 completed Report 8:00 the Report 8:01 Clarity Family launch in Japan, and initial customer response has been encouraging. Turnin… Report 8:21 Regarding myopia management, my site delivered another strong quarter with 20% organic gro… Report 8:41 ongoing launch of MyDay MySite with back to school campaigns highlighting the benefits of … Report 9:00 myopia management in children through spherical, torque, multifocal, and premium lifestyle… Report 9:20 the stage for a promising 2027 supported by continued momentum in existing markets and the… Report